New Nipah Vaccine: Phase 1 Shows Safety, Immune Response in Humans

A novel Nipah virus vaccine candidate, HeV-sG-V, has successfully completed Phase 1 human trials, demonstrating a good safety profile and eliciting a strong immune response. This development marks a crucial step towards preventing future deadly Nipah outbreaks, particularly in affected regions like India.

• HeV-sG-V vaccine shows safety and immune response in Phase 1 trial.
• Study published in The Lancet on December 13, 2025, confirms positive results.
• Two doses of the vaccine proved more effective in generating antibodies.
• Indian experts laud findings as a 'milestone' in vaccine development.
• Nipah virus is a high-priority pathogen with significant fatality rates.
• No approved Nipah vaccine currently exists globally, highlighting urgency.

Read the full story on Quick Digest.